NuCana (NCNA) Cash from Financing Activities (2017 - 2025)
NuCana's (NCNA) quarterly Cash from Financing Activities came in at $9311.2 in Q4 2025, down 99.67% year-on-year from $2.8 million in Q4 2024, and down 99.95% quarter-over-quarter from $20.6 million in Q3 2025.
NuCana (NCNA) Cash from Financing Activities (2017 - 2025) Analysis & Trends
NuCana has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $9311.2 for Q4 2025.
- Cash from Financing Activities for Q4 2025 came in at $9311.2, down 99.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $29.5 million (up 178.93% YoY), and the FY2025 annual result was $33.0 million, up 215.16% from the prior year.
- Cash from Financing Activities came in at $9311.2 for Q4 2025 at NuCana, down from $20.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $20.6 million in Q3 2025 to a low of -$103431.9 in Q2 2021.
- The 5-year median for Cash from Financing Activities is -$44807.7 (2022), against an average of $1.7 million.
- Across the five-year window, Cash from Financing Activities tumbled 268.52% in 2023 and soared 7394.38% in 2024, its largest moves.
- NuCana's Cash from Financing Activities stood at -$99752.8 in 2021, then jumped by 131.75% to $31669.1 in 2022, then tumbled by 268.52% to -$53369.5 in 2023, then surged by 5354.78% to $2.8 million in 2024, then sank by 99.67% to $9311.2 in 2025.
- The last three Cash from Financing Activities figures came in at $9311.2 (Q4 2025), $20.6 million (Q3 2025), and $2.8 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 85,464.43 |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | 9,311.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9,311.16 |
| Dec 31, 2025 | 9,311.16 |
| Sep 30, 2025 | 20.56 Mn |
| Sep 30, 2025 | 20.56 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Dec 31, 2024 | 2.80 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Sep 30, 2024 | 6.08 Mn |
| Jun 30, 2024 | -79,519.91 |
| Jun 30, 2024 | -79,519.91 |
| Mar 31, 2024 | 1.76 Mn |
| Mar 31, 2024 | 1.76 Mn |
| Dec 31, 2023 | -53,369.53 |
| Dec 31, 2023 | -53,369.53 |
| Sep 30, 2023 | 81,067.83 |
| Sep 30, 2023 | 81,067.83 |
| Jun 30, 2023 | -41,294.98 |
| Jun 30, 2023 | -41,294.98 |
| Mar 31, 2023 | -49,835.89 |
| Mar 31, 2023 | -49,835.89 |